# Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome

> **NCT00110422** · PHASE4 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 400 (—)

## Conditions studied

- Metabolic Syndrome
- Hypertension

## Interventions

- **DRUG:** Irbesartan
- **DRUG:** Hydrochlorothiazide

## Key facts

- **NCT ID:** NCT00110422
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 400 (—)
- **Last updated:** 2011-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00110422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00110422, "Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00110422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*